PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
-30.37%
Negative gross profit growth while TRAW is at 1.89%. Joel Greenblatt would examine cost competitiveness or demand decline.
-24.83%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.83%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-17.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-12.12%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-9.09%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
5.06%
Share count expansion well above TRAW's 0.05%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.04%
Diluted share count expanding well above TRAW's 0.05%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-120.47%
Negative OCF growth while TRAW is at 7.45%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-120.93%
Negative FCF growth while TRAW is at 7.45%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-252.09%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.56%
5Y OCF/share CAGR is similar to TRAW's 99.89%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
77.71%
3Y OCF/share CAGR at 75-90% of TRAW's 98.07%. Bill Ackman would press for improvements in margin or overhead to catch up.
99.67%
Similar net income/share CAGR to TRAW's 99.88%. Walter Schloss would see parallel tailwinds or expansions for both firms.
85.97%
5Y net income/share CAGR at 75-90% of TRAW's 99.84%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
69.72%
3Y net income/share CAGR 50-75% of TRAW's 97.70%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
173.45%
Equity/share CAGR of 173.45% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-62.01%
Negative 5Y equity/share growth while TRAW is at 101.01%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
56.61%
3Y equity/share CAGR at 50-75% of TRAW's 110.81%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-13.24%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-1.77%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
45.24%
R&D growth drastically higher vs. TRAW's 76.50%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-4.95%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.